Citations

Mayo Clinic

Showing 10 of 108572 citations.

Medial Collateral Ligament Reconstruction of the Knee: The Modified Marx Technique With Adjustable‐Loop Femoral Fixation and Posteromedial Corner Plication
Boos, Alexander M. , Hevesi, Mario , Wang, Allen S. , Fiegen, Anthony P. , Levy, Bruce A. , Wang, Allen , Boos, Alexander , Hevesi, Mario

Arthroscopy Techniques | December 25, 2023 | Volume: 13 | Issue: 1 | Pages: No page available

10.1016/j.eats.2023.09.007 | PMID 38312880 Get It

Abstract The medial collateral ligament serves as the primary stabilizer to valgus stress on the medial side of the knee and is the most commonly injured ligament in the knee. Medial collateral ligament reconstruction can provide improved stability and clinical outcomes for patients. Advancements in techniques, including the use of an adjustable‐length‐loop suspensory fixation device through a longitudinal incision, have been introduced in recent years. The purpose of this Technical Note and video is to provide a minimally invasive method for medial collateral ligament reconstruction with adjustable‐loop femoral fixation and posteromedial corner plication. Technique Video video See video under supplementary data.
Easy‐to‐use personalized legal and financial planning tool for AD/ADRD caregivers and persons with dementia
Lunde, Angela , Forsberg, Leah K. , Seifert, Sara J. , Kramer, K. , Knutson, Matthew , Rethemeier, Nicholas, Fields, Julie A.

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S11 | Pages: No page available

10.1002/alz.082180 Get It

Abstract Background Financial management is one of the most cited sources of stress among caregivers. Legal planning presents additional challenges. Only a small percentage of dementia caregivers report successfully completing necessary planning. Further, persons with dementia are vulnerable to fraud, scam, and inappropriate financial transactions. With stakeholder participation, we explored a novel solution using state‐of‐the‐art technology aimed to overcome impediments that have plagued prior legal and financial planning resources. Method 18 stakeholders from 10 organizations across the U.S. serving persons with dementia and caregivers participated in two 60 to 90‐minute semi‐structured interviews that were recorded and transcribed. Qualitative stakeholder input was collected through an iterative process. During initial interviews, a mockup was shared to elicit feedback. There was a 3‐month wait after the first interviews to incorporate recommendations into the evolving prototype. During the second round of interviews, stakeholders evaluated the prototype progress based on feedback they previously provided. Stakeholders then completed an electronic survey to assess their overall confidence in the value of the future tool. A phase 1 prototype was designed using Adobe XD. Stakeholders influenced the content, layout, colors, and images with goals of clarity, usability, legibility, and simplicity. Included are a ‘how the tool works’ section; a wizard that guides users through a topic by asking questions, responding appropriately, a prioritized to‐do list; a chatbot; and a dashboard for viewing progress and sharing with selected care partners. Responses to questions were generated by legal and financial experts. Result All 18 stakeholders confirmed that financial management and legal planning are highly stressful for persons with dementia and their families and that there is a need for a tool of this type. 85% of the stakeholders indicated that were extremely satisfied, or very satisfied that the tool would be a beneficial product. Conclusion Results confirmed the need for and utility of an easy‐to‐use tool assisting in legal and financial planning. Phase 2 will incorporate additional content and features along with further review from legal and financial experts. Persons living with dementia and care partners will be included in the testing, evaluation, and further refinement of the technology tool.
Curriculum‐based CME Programming Results in Comprehensive Improvements in Knowledge, Competence, and Confidence in Diagnosing Early Forms of Alzheimer’s Disease Among a Global Audience of PCPs and Neurologists
Finnegan, Thomas , Stan, Adriana, McFarland, Frances, Chatterjee‐Shin, Piyali, Guedj, Philippe, Cohen, Sharon , Petersen, Ronald C.

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S11 | Pages: No page available

10.1002/alz.082156 Get It

Abstract Background Early diagnosis of Alzheimer’s disease (AD) is crucial for ensuring patients have timely access to essential care. Given the symptoms of early AD are often subtle, it is important that both primary care physicians (PCPs) and neurologists are able to diagnose their patients. Several sources of evidence have indicated that most PCPs and neurologists lack knowledge, competence, and confidence regarding recognition of early forms of AD. To address the clinical practice gaps, a series of CME‐certified programs covering the symptoms, assessment, and diagnosis of early forms of AD were developed. Method The data presented here are based on outcomes from four online CME‐certified multimedia programs housed on a single destination page. Each CME‐certified program utilized expert physicians to educate learners on recognizing early forms of AD. Each CME program asked a series of pre‐post questions designed to assess immediate changes in knowledge, competence, or confidence. The questions were grouped into clinically relevant themes. The educational effect for all of the programs was determined by using a paired‐samples t‐test to identify significant differences between pre‐ and post‐assessment responses for each question. Data across all four programs were collected from February 2022 through December 2022. All four programs were promoted to an audience of US‐ and ex‐US physicians. Result Participation across the four programs ranged from 543 to 2,510 PCPs and 256 to 1,025 neurologists. PCPs and neurologists demonstrated significant (P<0.05) pre‐vs post education improvements on the following themes: biomarkers in AD, clinical trial outcomes, cognitive assessment scales, diagnosis of AD, diagnosis of mild cognitive impairment (MCI), and symptoms differentiating AD from MCI. Participation in the education also significantly (P<0.001) improved confidence in the identification of early forms of AD among PCPs and neurologists. No substantial differences in knowledge, competence, or confidence were seen for either clinician group based on geographic location of the learner. Conclusion The results indicated that clinicians who participated in CME‐certified curriculum‐based education in multiple formats were better prepared to recognize early forms of AD. Future education should continue to discuss the use of clinical strategies to recognize early forms of AD.
Continuous associations between remote self‐administered cognitive measures and amyloid and tau PET biomarkers of Alzheimer’s disease
Frank, Ryan D. , Fan, Winnie Z. , Christianson, Teresa J., Karstens, Aimee J. , Stricker, John L. , Fields, Julie A. , Graff‐Radford, Jonathan , Petersen, Ronald C. , Boots, Elizabeth A. , Karstens, Aimee James , Kremers, Walter K. , Machulda, Mary M. , Hassenstab, Jason , Vemuri, Prashanthi , Jack, Clifford R. , Knopman, David S. , Mielke, Michelle M. , Stricker, Nikki H.

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S11 | Pages: No page available

10.1002/alz.082144 Get It

Abstract Background Easily accessible and self‐administered cognitive assessments that can aide early identification of individuals at risk for Alzheimer’s disease (AD) dementia are critical for timely intervention. Mayo Test Drive (MTD) is a remote, self‐administered, multi‐device compatible, web‐based cognitive assessment (Stricker et al., 2022). We investigated continuous associations between MTD and amyloid and tau PET biomarkers and compared the strength of association to PET biomarkers and in‐person cognitive measures. Method 556 adults from the Mayo Clinic Study of Aging participated (mean age = 70.6; mean education = 16.0 years; 50.7% female; 97.5% white). Participants were predominantly cognitively unimpaired (95.3%; 4.7% had a consensus diagnosis of mild cognitive impairment). Participants completed (1) brain amyloid and tau PET scans, (2) in‐person neuropsychological assessment including Mayo Preclinical Alzheimer’s disease Cognitive Composite (Mayo‐PACC) and Global‐z, and (3) remote MTD comprised of the Stricker Learning Span (SLS) and the Symbols test, which are combined into an MTD composite. Multiple regressions adjusted for age, sex, and education queried associations between imaging biomarkers [amyloid meta‐region of interest (ROI), tau meta‐ROI, and tau entorhinal cortex (EC)‐ROI)] and composite and subtest scores from remote and in‐person measures. Davidson‐Mackinnon J‐test compared R‐squared values of models with remote versus in‐person composites. Result Lower performances on MTD composite and Mayo‐PACC were associated with higher amyloid meta‐ROI (p’s<.05; Table 1). MTD composite was also negatively associated with tau meta‐ROI and EC‐ROI (p’s<.05). For memory measures, SLS sum of trials was negatively associated with tau meta‐ROI (p = .01) and EC‐ROI (p<.001) with no associations between AVLT sum of trials and PET (p’s = .06; Table 2). Among processing speed/executive function measures, worse Trails B performance was associated with higher amyloid meta‐ROI (p<.001). Symbols and Digit Symbol Coding were not associated with PET (p’s = .29). A multivariable model with MTD explained significantly less variance (p = .04) for amyloid meta‐ROI (adjusted R‐squared = 0.165) than a multivariable model with Mayo‐PACC (adjusted R‐squared = 0.176); remote and in‐person composite measures were comparable for other associations (p’s>.05). Conclusion MTD is associated with continuous measures of amyloid and tau PET biomarkers of AD, demonstrating criterion validity for MTD. Several associations were comparable to relationships between gold‐standard in‐person neuropsychological tests and imaging biomarkers.
Baseline and Six‐Month Actigraphy and Sleep‐monitoring Devices Help Differentiate Between Alzheimer’s Disease and Dementia with Lewy Bodies
Brown, Karl, Shutes‐David, Andrew, Payne, Sarah, Jankowski, Adrienne, Levendowski, Daniel J. , Wilson, Katie , Tsuang, Debby W. , Shutes‐David, Andrew , Seto, Edmund , Louis, Erik K. St.

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S11 | Pages: No page available

10.1002/alz.082101 Get It

Abstract Background Dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD) are challenging to differentiate. Mobile health devices that measure motor and sleep domains between clinic visits may improve differential diagnosis. Method Participants with probable AD and probable DLB wore ActiGraph triaxial wGT3X‐BT actigraphy devices on their nondominant wrists for 2 weeks and multichannel Sleep ProfilerX8TM EEG devices on their foreheads for 2 consecutive nights.3 Actigraphy data were processed and scored using GGIR and activity counts in R. The Sleep Profiler characterizes abnormal slow‐wave sleep and non‐REM hypertonia (NRH). Result At baseline, participants with DLB (n = 9) had higher UPDRS scores and a higher likelihood of psychosis than participants with AD (n = 8; see Table 1). Using univariate Wilcoxon Rank‐Sum tests, we found that at baseline participants with DLB had lower daily activity counts, higher % time in NRH, and lower % time in REM sleep than participants with AD (unadjusted p‐values < 0.05; See Figure 1). In a recent 6‐month followup, activity levels were lower on average than baseline activity levels for both DLB (n = 5) and AD (n = 5). at 6‐months, the differences in % sleep in NRH increased between DLB participants (n = 5) and AD participants (n = 3) as average % NRH increase 6% in DLB and decreased 1% in AD (see Table 2). These 6‐month differences are not statistically significant, but data collection are ongoing. An exploration of methods for processing and scoring actigraphy data revealed that processing can result in wide range of findings. As a result, we have focused on actigraphy outcomes which are more suitable to older participants with dementia. Conclusion Participants with DLB demonstrated lower baseline physical activity and higher rates of baseline sleep disturbances than participants with AD; sleep differences between DLB and AD appeared to increase over 6 months. Actigraphy and sleep‐monitoring devices are well tolerated in participants with dementia and they can reliably collect valid, useful activity and sleep data in between clinic visits.
Comparing associations of Alzheimer’s disease plasma biomarkers with remote self‐administered cognitive measures versus in‐person neuropsychological tests
Frank, Ryan D. , Fan, Winnie Z. , Christianson, Teresa J., Karstens, Aimee J. , Stricker, John L. , Fields, Julie A. , Graff‐Radford, Jonathan, Petersen, Ronald C. , Boots, Elizabeth A. , Karstens, Aimee James , Kremers, Walter K. , Machulda, Mary M. , Hassenstab, Jason , Graff‐Radford, Jonathan , Vemuri, Prashanthi , Jack, Clifford R. , Knopman, David S. , Mielke, Michelle M. , Stricker, Nikki H.

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S11 | Pages: No page available

10.1002/alz.082087 Get It

Abstract Background Brief self‐administered cognitive assessments deployed remotely and combined with plasma biomarkers of Alzheimer’s disease (AD) are well suited to assess clinical symptoms and underlying biology in large‐scale decentralized studies. We investigated whether associations of self‐administered cognitive measures and plasma biomarkers were comparable to associations of in‐person cognitive measures and plasma biomarkers. Method Participants included 327 adults from the Mayo Clinic Study of Aging (mean age = 70.8; 48% female; mean education = 16.0 years; 96.9% white). Most (94.5%) were cognitively unimpaired; 5.5% had consensus diagnosis of mild cognitive impairment. Participants completed Mayo Test Drive (MTD; Stricker et al., 2022), a remote, self‐administered, multi‐device compatible web‐based cognitive assessment comprised of the Stricker Learning Span (SLS) and Symbols test that are combined into a MTD composite. Participants also completed in‐person neuropsychological assessment (global‐z; Mayo Preclinical Alzheimer’s disease Cognitive Composite [Mayo‐PACC]) and fasting venipuncture. Plasma was assayed via HD‐X simoa platform for amyloid‐beta (Aß)‐42 and Aß‐40 to create an Aß42/40 ratio, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) using the N4PE Quanterix kit as well as phosphorylated‐tau protein 181 (p‐tau181). P‐tau181, GFAP, and NfL were log10‐transformed. Multiple regression analyses adjusting for age, sex, and education examined associations between plasma biomarkers and composite and subtest scores from remote and in‐person measures. Davidson‐Mackinnon J‐test compared R‐squared values of models with remote versus in‐person composites. Result Lower performances on MTD, global‐z, and Mayo‐PACC (Table 1) were associated with higher GFAP (p’s = .02), NfL (p’s = .003), and p‐tau181 (p’s = .04). For memory, worse SLS and AVLT sum of trials were associated with higher GFAP (p’s = .01) and NfL (p’s = .03). For processing speed/executive function, worse Symbols and Trails B were associated with higher p‐tau181 (p’s = .02). Worse Trails B and Digit Symbol Coding were associated with higher NfL (p’s = .02), and worse Digit Symbol Coding was associated with lower Aß42/40 (p = 0.03; Table 2). A multivariable model with MTD explained significantly more variance (p = .04) for NfL (adjusted R‐squared = 0.461) than a multivariable model with Mayo‐PACC (adjusted R‐squared = 0.447); remote and in‐person composite measures were comparable for other associations (p’s>.05). Conclusion Remote and in‐person composite measures showed comparable associations with AD‐related plasma biomarkers, supporting MTD’s criterion validity.
Treatment of pyoderma gangrenosum in pregnancy with certolizumab pegol
Wanberg, Lindsey J , Fletcher, Kathleen M., Alavi, Afsáneh , Alavi, A , Goldfarb, Noah

JEADV Clinical Practice | December 25, 2023 | Volume: 3 | Issue: 2 | Pages: 696-698

10.1002/jvc2.346 Get It

AbstractWe report a case of a 41‐year‐old woman who developed pregnancy‐associated pyoderma gangrenosum (PG) at 4 weeks gestation. She was initially treated with prednisone, however, due to lack of improvement and risk of systemic corticosteroids in pregnancy, underwent a prednisone taper and was initiated on certolizumab pegol (CZP). The patient experienced complete wound re‐epithelialization 1 month after CZP initiation. She had no pregnancy complications except for prednisone‐associated gestational diabetes and gave birth to a healthy baby. CZP is a tumour necrosis factor‐inhibitor with negligible placental transfer and no known adverse effects in pregnancy. Its efficacy and safety for autoinflammatory dermatoses in pregnancy are very promising. This is the first case to report CZP treatment for PG in a pregnant patient.
Plasma biomarkers of Alzheimer´s disease in the continuum of dementia with Lewy bodies
Przybelski, Scott A. , Lesnick, Timothy G. , Gunter, Jeffrey L. , Jain, Manoj , Miyagawa, Toji , Forsberg, Leah K. , Fields, Julie A. , Savica, Rodolfo , Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Petersen, Ronald C. , Lowe, Val J. , Diaz‐Galvan, Patricia , Algeciras‐Schimnich, Alicia , Schwarz, Christopher G. , Senjem, Matthew L. , Jack, Clifford R. , Min, Hoon-Ki Paul , Ramanan, Vijay K. , Jones, David T. , Botha, Hugo , Louis, Erik K. St. , Knopman, David S. , Ferman, Tanis J. , Boeve, Bradley F. , Kantarci, Kejal

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S10 | Pages: No page available

10.1002/alz.082040 Get It

AbstractBackgroundPatients with dementia with Lewy bodies (DLB) may have Alzheimer´s disease (AD) pathology. Plasma biomarkers of beta‐amyloid (Aß), phosphorylated tau (pTau), and neurodegeneration are sensitive to AD neuropathologic changes in AD dementia. While these plasma biomarkers are well tested in the AD continuum, their performance for concomitant AD pathology in the DLB continuum is still unclear.MethodWe included patients with isolated REM sleep behavior disorder (iRBD; n = 15), with mild cognitive impairment with Lewy bodies (MCI‐LB; n = 37), and with DLB (n = 70) from the Mayo Clinic Alzheimer’s Disease Research Center. Cognitively unimpaired individuals (CU; n = 100) included from the Mayo Clinic Study of Aging were balanced on age and sex. A panel of plasma biomarkers of Aß40, Aß42, p‐tau181, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) measures was obtained. We calculated the ratio of plasma Aß40/42. Lower Aß40/42 indicates increased Aß pathology. Plasma Aß40, Aß42, GFAP, and NfL were measured using the Simoa® Neurology 4‐Plex E Advantage kit and pTau‐181 was measured with the Simoa® pTau‐181 Advantage V2 kit. Both were run on a Quanterix HD‐X analyzer. AD imaging biomarkers were assessed on PET using Pittsburgh compound B (PiB) for Aß and 18F‐Flortaucipir for tau.ResultHigher levels of plasma GFAP were observed in the MCI‐LB (p = 0.014) and DLB (p<0.001) groups compared to CU (Figure). DLB patients also showed higher levels of plasma pTau181 (p<0.001) and NfL (p<0.001). Higher amyloid and tau PET standardized uptake value ratio (SUVr) in the DLB continuum were associated with higher levels of plasma p‐tau181, NfL, and GFAP (p<0.001). After accounting for age, plasma Aß40/42 did not correlate with amyloid or tau PET SUVr.ConclusionIn the DLB continuum, abnormal levels of GFAP in plasma can be detected as early as the prodromal stages of the disease. Plasma pTau181 reached abnormal levels in the DLB stage. Higher plasma GFAP, NfL, and p‐tau181 are associated with higher amyloid and tau PET SUVr in the DLB continuum. Plasma biomarkers have the potential to contribute to screening and early diagnosis in the DLB continuum, which has implications in designing new treatments.
Concordance between visual interpretation and quantitative analysis of [18F]flortaucipir pet images
Raghavan, Sheelakumari , Sparrman, Kohl Johnson, Costoya‐Sánchez, Alejandro , Mainta, Isminni, Devous, Michael D. , Pontecorvo, Michael J. , Petersen, Ronald C. , Rial, Alexis Moscoso , Heeman, Fiona , Camacho, Valle , Essen, Martijn van , Grothe, Michel J. , Ribaldi, Federica , Frisoni, Giovanni B. , Garibotto, Valentina , Jack, Clifford R. , Vemuri, Prashanthi , Schöll, Michael

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S10 | Pages: No page available

10.1002/alz.082007 Get It

AbstractBackgroundPositron emission tomography (PET) imaging with [18F]flortaucipir allows for in‐vivo visualization of aggregated tau in Alzheimer’s disease (AD). The FDA‐approved label for [18F]flortaucipir PET provides a standardized, clinically applicable definition of tau‐PET positivity by visual interpretation. Here, we studied the concordance between this visual interpretation and quantitative approaches employed in research.MethodWe included 2692 participants (cognitively unimpaired [CU] and impaired [CI, MCI or AD dementia]) from four cohorts (Mayo Clinic Study of Aging and ADRC, ADNI, A4, and A05) with available [18F]flortaucipir PET (mean age: 70.2 y, 50.0% females). Three trained readers assessed each [18F]flortaucipir PET scan according to the FDA‐approved method. Visual reads were compared to an established approach for defining tau‐PET positivity based on SUVR values in a temporal meta‐ROI (Jack, et al. Alzheimers Dement. 2017). Previously defined “lenient” (SUVR = 1.22) and “conservative” (SUVR = 1.30) cut‐points were explored. In addition, visual reads were compared to tau‐PET positivity as defined by a scheme based on the expected spatial progression of tau pathology from the medial temporal lobe (MTL) to the temporal neocortex (NEO) (Ossenkoppele, et al. Nat Med. 2022; cut‐points: SUVRMTL = 1.30, SUVRNEO = 1.37).ResultConcordance between visual and quantitative approaches was limited (Figure 1): the “lenient” and MTL‐NEO methods yielded high rates of quantitative‐positive, visual‐negative scans (73‐52% and 26‐18% for CU and CI, respectively), while the “conservative” cut‐point failed to detect 45% and 13% of the CU and CI visual‐positive scans, respectively. The prevalence of tau‐PET positivity in Aß‐negative individuals was highest with the “lenient” cut‐point (∼24%) and lowest with visual interpretation (∼3%) (Figure 2). Visual‐positive, quantitative‐negative individuals were more frequently Aß‐positive than visual‐negative, quantitative‐positive individuals (“lenient”: 86% vs 50%, p<0.001; “conservative”: 87% vs 58%, p<0.001; MTL‐NEO: 85% vs 70%, p = 0.005). Among visually‐positive participants, 164 (28%) showed a tau deposition pattern that deviated from the expected MTL to NEO progression (Figure 3).ConclusionVisual and quantitative methods for [18F]flortaucipir PET are non‐exchangeable. Tau‐PET positivity based on visual interpretation aligns better with Aß‐pathology. A significant number of visually‐positive participants showed a pattern of tau accumulation that deviated from the expected stereotypical spatial progression and was not detected by standard quantitative methods.
Cohort heterogeneity and AD biomarkers in older adults without significant cognitive impairment: A comparison of U.S. POINTER and ADNI
Landau, Susan , Baker, Suzanne L. , Lovato, Laura, Masdeu, Joseph C. , Oh, Hwamee , Aggarwal, Neelum T. , Farias, Sarah Tomaszewski , Snyder, Heather M. , Jagust, William J. , Harrison, Theresa M. , Ward, Tyler J. , Koeppe, Robert A. , Vemuri, Prashanthi , Lockhart, Samuel N. , Jung, Youngkyoo , Harvey, Danielle , Toga, Arthur W. , Masdeu, Joseph C , Gitelman, Darren R. , Papp, Kathryn V. , Baker, Laura D. , DeCarli, Charles

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S10 | Pages: No page available

10.1002/alz.081990 Get It

AbstractBackgroundA key focus of the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) is recruitment of unimpaired older individuals at risk for cognitive decline with heterogeneous characteristics (under‐represented racial and ethnicity groups (URG), family history of cognitive decline, hypertension, geographic diversity), and a subset of individuals undergo PET and MRI.MethodTo examine effects of heterogeneity on relationships between risk factors, AD biomarkers (Aß and entorhinal tau PET, hippocampal volume (HV)) and cognition (global, executive function, and memory) were examined from U.S. POINTER neuroimaging participants (N = 602, about 65% of the anticipated total sample) and a subset of Alzheimer’s Disease Neuroimaging Initiative participants (N = 503). Neuroimaging data were processed and analyzed using harmonized methods across studies. Some cohort‐specific measurements were standardized using a within‐cohort reference group (Aß‐negative individuals <70yrs and with global CDR = 0).ResultU.S. POINTER imaging participants are younger than those in ADNI (68.6+/‐5.0yrs vs 70.7+/‐4.4yrs), more likely to be female (65% vs 58%) and from URG (27% vs 15%), and had lower education (14.7+/‐3.3yrs vs 16.7+/‐2.3yrs) and higher Framingham Cardiovascular Risk scores (9.9+/‐8.3 vs 7.7+/‐5.3). The groups differed on several AD biomarkers and cognitive measures (Table). In regression models, AD biomarkers were stronger predictors of cognitive performance in ADNI compared to POINTER. Specifically, Aß+ individuals with elevated tau had disproportionately poorer cognitive performance in ADNI, and this relationship remained consistent across cognitive measures (Figure). Conversely, demographic/risk variables were stronger predictors in POINTER. Demographic/risk predictors (age, sex, education, race, and FRS) together explained twice as much variance in global cognition in POINTER compared to ADNI (Adjusted R2 = 29% vs 14%). The addition of AD biomarkers to the model further increased the amount of variance in global cognition explained from 14% to 34% in ADNI, but addition of AD biomarkers did not increase variance explained in the POINTER model.ConclusionHeterogeneity among study participants appears to influence baseline biomarker‐cognition relationships such that AD biomarkers explain more variability in cognitive performance in ADNI than POINTER. These findings further suggest that cohort characteristics may affect the potential influence of amyloid‐ and tau‐modifying treatments on cognition.